Indo US Bio-Tech Board of Directors
Get the latest insights into the leadership at Indo US Bio-Tech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Jagdish Ajudia | Managing Director |
| Mrs. Maltlben Ajudia | Whole Time Director |
| Ms. Priyanka Ajudia | Executive Director |
| Mrs. Neha Patel | Ind. Non-Executive Director |
| Mrs. Shilpa Thumar | Ind. Non-Executive Director |
| Mrs. Ritaben Nileshbhai Kikani | Ind. Non-Executive Director |
Indo US Bio-Tech Share price
INDOUS
135.5
0.39 (-0.29%)NSE
BSE
Last updated on 4 Nov, 2025 | 15:29 IST
BUYSELL
Today's High
140.67
Today's Low
128.71
52 Week Low
119.39
52 Week High
388.40
The current prices are delayed, login to your account for live prices
LoginIndo US Bio-Tech FAQs
The board at Indo US Bio-Tech consists of experienced professionals, including Mr. Jagdish Ajudia , Mrs. Maltlben Ajudia , and others, overseeing the company’s strategic and corporate governance.
Directors at Indo US Bio-Tech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Jagdish Ajudia is the current chairman at Indo US Bio-Tech.
Executive directors at Indo US Bio-Tech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Indo US Bio-Tech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Indo US Bio-Tech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.